We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-18.41%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.33B
AUM Growth
-$282M
Cap. Flow
+$75M
Cap. Flow %
5.64%
Top 10 Hldgs %
73.79%
Holding
45
New
1
Increased
3
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
TEM
Tempus AI
TEM
+$140M
2
VRNA
Verona Pharma
VRNA
+$6.95M
3
GOSS icon
Gossamer Bio
GOSS
+$1.69M
4
KRRO icon
Korro Bio
KRRO
+$987K

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$39M
2
ZFOX
ZeroFox Holdings, Inc. Common Stock
ZFOX
+$20.2M
3
CBIO
Crescent Biopharma
CBIO
+$11.5M
4
TUYA
Tuya Inc
TUYA
+$3.04M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$926K

Sector Composition

Rank Sector Weight
1 Healthcare 85.63%
2 Consumer Staples 6.93%
3 Technology 6.18%
4 Communication Services 0.8%
5 Industrials 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$207M 15.55%
3,745,262
– –
TEM
2
Tempus AI
TEM
$7.64B
$160M 12.04%
+4,572,810
New +$140M
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.4B
$119M 8.99%
2,909,956
– –
SVRA icon
4
Savara
SVRA
$1.08B
$98.6M 7.42%
24,471,264
– –
COUR icon
5
Coursera
COUR
$1.72B
$92.1M 6.93%
12,867,769
– –
CRSP icon
6
CRISPR Therapeutics
CRSP
$4.64B
$85.8M 6.45%
1,587,854
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$80.8M 6.08%
5,584,753
+476,190
+9% +$6.95M
NN icon
8
NextNav
NN
$1.77B
$66.4M 5%
8,189,156
– –
KRRO icon
9
Korro Bio
KRRO
$150M
$36.9M 2.78%
1,090,793
+17,857
+2% +$987K
TRVI icon
10
Trevi Therapeutics
TRVI
$2.6B
$33.9M 2.55%
11,370,376
– –
GLUE icon
11
Monte Rosa Therapeutics
GLUE
$1.85B
$28.8M 2.16%
7,692,298
– –
CVRX icon
12
CVRx
CVRX
$132M
$28.4M 2.14%
2,370,542
– –
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$1.92B
$22.7M 1.71%
3,969,834
– –
NKTX icon
14
Nkarta
NKTX
$157M
$21.1M 1.59%
3,568,781
– –
BDTX icon
15
Black Diamond Therapeutics
BDTX
$98M
$20.7M 1.56%
4,448,757
– –
CELC icon
16
Celcuity
CELC
$3.99B
$20.5M 1.54%
1,250,001
– –
PHAT icon
17
Phathom Pharmaceuticals
PHAT
$933M
$20.2M 1.52%
1,960,169
– –
ADAP
18
DELISTED
Adaptimmune Therapeutics
ADAP
$16.7M 1.25%
17,079,778
– –
GOSS icon
19
Gossamer Bio
GOSS
$92.7M
$16.3M 1.23%
18,093,034
+2,255,025
+14% +$1.69M
NEUE
20
DELISTED
NeueHealth
NEUE
$14.8M 1.12%
2,726,917
– –
GERN icon
21
Geron
GERN
$905M
$11.8M 0.89%
2,776,409
-10,000,000
-78% -$39M
RGLS
22
DELISTED
Regulus Therapeutics
RGLS
$11.6M 0.87%
6,467,802
– –
INZY
23
DELISTED
Inozyme Pharma
INZY
$10.9M 0.82%
2,437,689
– –
ORIC icon
24
Oric Pharmaceuticals
ORIC
$1.2B
$10.6M 0.8%
1,500,000
– –
BZFD icon
25
BuzzFeed
BZFD
$99.9M
$10.6M 0.8%
3,833,473
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q2 2024 Portfolio in Review

As of Q2 2024, NEA Management Company held 45 positions worth $1.33B, down 18% from $1.61B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

NEA Management Company deployed $75M of net new capital in Q2 2024, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Tempus AI: 4,572,810 shares worth $160M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Geron, an estimated $39M trimmed.

  • NEA Management Company's largest Q2 2024 buy was Tempus AI: 4,572,810 shares worth $160M.
  • NEA Management Company added most to Verona Pharma in Q2 2024, an estimated $6.95M increase.
  • NEA Management Company's biggest Q2 2024 reduction was Geron, cutting an estimated $39M.
  • NEA Management Company fully exited ZeroFox Holdings, Inc. Common Stock in Q2 2024, selling an estimated $20.2M.
  • NEA Management Company's ten largest holdings make up 74% of its $1.33B portfolio in Q2 2024.
  • NEA Management Company opened 1 new position and closed 4 in Q2 2024.
  • NEA Management Company's portfolio value fell 18% quarter-over-quarter to $1.33B.

Based on NEA Management Company's 13F filing for Q2 2024, filed 14 Aug 2024.